Objective: Statins are highly effective medications for reducing low-density lipoprotein cholesterol concentrations and cardiovascular events. Their most common side effects are a variety of myopathic complaints, possibly due to reduced circulating Coenzyme Q10 (CoQ10) levels. We sought to determine whether CoQ10 supplementation decreases the rate of myalgia in patients with statin-related myalgia.
Introduction
Statins or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are the most effective medications for reducing low-density lipoprotein cholesterol concentrations, and cardiovascular morbidity and mortality. Although generally safe, their most serious and frequent side effects are myopathic complaints 1, 2 . CoQ10 is a naturally occurring, fat-soluble quinone participating in electron transport during oxidative phosphorylation in mitochondria, which protects against oxidative stress produced by free radicals 3 , and regenerates active forms of the antioxidants ascorbic acid and tocopherol (vitamin E) 4, 5 .
Statins block production of farnesyl pyrophosphate, an intermediate in the production of CoQ10. Statins have been shown to reduce serum levels of CoQ10 16% to 38% [6] [7] [8] [9] [10] [11] . This fact plus the role of CoQ10 in mitochondrial energy production and the importance of mitochondria in muscle function has prompted the hypothesis that statin-induced CoQ10 deficiency contributes to in statin-associated myopathy.
The present study was designed to evaluate whether CoQ10 supplementation would reduce myalgic symptoms in patients with statin-induced myalgia.
Methods
The study was a randomized double-blind, placebo-controlled study.
Patients were recruited from cardiology clinics. 
Results
A total of 37 patients were recruited, of them 20
in the placebo group and 17 in the CoQ10 group.
Both groups had similar baseline characteristics (Table 1 ).
All patients tolerated Coenzyme Q10 well, and adhered to the study protocol for the first 4 weeks. As the study progressed seven patients in the placebo group and 3 patients in the Coenzyme Q10 group withdrew from the study, however this difference was not statistically significant (table 2). All patients withdrew from the study did so for the same reason:
futility of the treatment prescribed to them (e.g. failure of the study drug to relief myalgia). There was no statistically significant difference between both groups when number of weeks of adherence to statin treatment of all patients was compared.
Both placebo and CoQ10 treated patients had myalgia of the same severity at the beginning of the study (Fig 1 and table 2 ). Only one patient (CoQ10 group) had a mildly elevated serum CPK level, all other patients of both groups had myalgia with normal CPK levels. Myalgia decreased gradually over time in both groups, however no difference was noted between the placebo and CoQ10 groups (Fig 1 and table 2) . 
Discussion

Positive Studies:
Caso G et al 13 randomized 32 patients with statin-associated myalgia to vitamin E 400 IU a day (14 patients) or CoQ10 100 mg a day (18 patients) daily.
After a 30-day intervention, pain severity decreased by 40% in the group treated with CoQ10. In contrast, no change in pain severity was observed in the group treated with vitamin E 13 . did not reveal such a trend. Although no conclusion can be made based on this observation given the limited study sample, it is possible that there is a gender difference in response to CoQ10.
Study Limitations
As in previous studies, the number of patients enrolled was relatively small.
We did not measure CoQ10 blood levels, however, our patients demonstrated a high level of adherence to the study drug, and studies have demonstrated that oral CoQ10 administration increases CoQ10 blood levels in patients treated with statins [22] [23] [24] .
Conclusion:
The present study does not suggest any benefit of CoQ10 supplementation in improving statin-induced myalgia. Differential gender response to CoQ10 should be evaluated in a larger prospective study. 
